LGM 2605

Drug Profile

LGM 2605

Alternative Names: LGM-2605

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Scripps Research Institute; University of Pennsylvania
  • Developer LignaMed; National Institute of Allergy and Infectious Diseases
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced damage; Lung disorders; Pulmonary fibrosis; Radiation injuries

Most Recent Events

  • 03 Jul 2017 LignaMed has patent protection for LGM 2605 (LignaMed website, July 2017)
  • 03 Jul 2017 LignaMed has patents pending for LGM 2605 (LignaMed website, July 2017)
  • 03 Jul 2017 Preclinical trials in Lung disorders in USA (PO) before July 2017 (LignaMed website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top